Evidence map›Paper›PMID 29766349›Full record

SynthesisCurrent atherosclerosis reports2018

Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review.

Jessica Ayers, Jamie Cook, Rachel A Koenig, Evan M Sisson, Dave L Dixon

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current atherosclerosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jessica AyersDepartment of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, 1112 E. Clay St., Box 980533, Richmond, VA, 23298-0533, USA.
Jamie CookDepartment of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, 1112 E. Clay St., Box 980533, Richmond, VA, 23298-0533, USA.
Rachel A KoenigTompkins-McCaw Library for the Health Sciences, VCU Libraries, Virginia Commonwealth University, Richmond, VA, USA.
Evan M SissonDepartment of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, 1112 E. Clay St., Box 980533, Richmond, VA, 23298-0533, USA.
Dave L DixonDepartment of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, 1112 E. Clay St., Box 980533, Richmond, VA, 23298-0533, USA. dldixon@vcu.edu.
Children's Hospital of Richmond at VCU · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review examines recent randomized clinical trials evaluating the role of coenzyme Q10 (CoQ10) in the management of coronary heart disease. RECENT

findingsCoQ10 is one of the most commonly used dietary supplements in the USA. Due to its antioxidant and anti-inflammatory effects, CoQ10 has been studied extensively for possible use in managing coronary heart disease. One of the most common applications of CoQ10 is to mitigate statin-associated muscle symptoms (SAMS) based on the theory that SAMS are caused by statin depletion of CoQ10 in the muscle. Although previous studies of CoQ10 for SAMS have produced mixed results, CoQ10 appears to be safe. Because CoQ10 is a cofactor in the generation of adenosine triphosphate, supplementation has also recently been studied in patients with heart failure, which is inherently an energy deprived state. The Q-SYMBIO trial found that CoQ10 supplementation in patients with heart failure not only improved functional capacity, but also significantly reduced cardiovascular events and mortality. Despite these positive findings, a larger prospective trial is warranted to support routine use of CoQ10. Less impressive are the effects of CoQ10 on specific cardiovascular risk factors such as blood pressure, dyslipidemia, and glycemic control. Current evidence does not support routine use of CoQ10 in patients with coronary heart disease. Additional studies are warranted to fully determine the benefit of CoQ10 in patients with heart failure before including it in guideline-directed medical therapy.

Indexed as

AntioxidantsBlood GlucoseCardiovascular DiseasesChronic DiseaseCoronary DiseaseDiabetes MellitusDietary SupplementsDyslipidemiasHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMuscular DiseasesRandomized Controlled Trials as TopicRisk FactorsUbiquinoneAntioxidantsBlood Glucosecoenzyme Q10Hydroxymethylglutaryl-CoA Reductase InhibitorsUbiquinoneCardiovascular diseaseCoenzyme Q10Heart failureMyalgiaStatins

Identifiers

PMID29766349
OpenAlexW2805018917

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.